[1] CHUNG HJ, MAHALINGAM M.Vasculogenic mimicry and vascular invasion incutaneous malignant melanoma-implications for therapeutic strategies and targeted therapies[J]. Expert Rev Anticancer Ther, 2014, 14(5): 621. doi: 10.1586/14737140.2014.883281
[2] MANIOTIS AJ, FOLBERG R, HESS A, et al. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry[J]. Am J Pathol, 1999, 155(3): 739. doi: 10.1016/S0002-9440(10)65173-5
[3] LIN X, SUN B, ZHU D, et al. Notch4+ cancer stem-like cells promotethe metastatic and invasive ability of melanoma[J]. Cancer Sci, 2016, 107(8): 1079. doi: 10.1111/cas.12978
[4] YUE WY, CHEN ZP.Does vasculogenic mimicry exist in astrocytoma?[J]. J Histochem Cytochem, 2005, 53(8): 997. doi: 10.1369/jhc.4A6521.2005
[5] ZHANG WX, ZHOU P, MENGET A, et al. Down-regulating Myoferlin inhibits the vasculogenic mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition[J]. J Cell Mol Med, 2018, 22(3): 1743. doi: 10.1111/jcmm.13455
[6] VARTANIAN AA.Signaling pathways in tumor vasculogenic mimicry[J]. Biochemistry Mosc, 2012, 77(9): 1044. doi: 10.1134/S000629791209012X
[7] FOLBERG R, MANIOTIS AJ.Vasculogenic mimicry[J]. APMIS, 2004, 112(7/8): 508.
[8] FOLBERG R, RUMMELT V, GINDERDEUREN R, et al. The prognostic value of tumor blood vessel morphology in primary uveal melanoma[J]. Ophthalmology, 1993, 100(9): 1389. doi: 10.1016/S0161-6420(93)31470-3
[9] FOSS AJ, ALEXANDER RA, HUNGERFORD JL, et al. Reassessment of the PAS patterns in uveal melanoma[J]. Br J Ophthalmol, 1997, 81(3): 240. doi: 10.1136/bjo.81.3.240
[10] LI C, CHEN YS, CHEN ZP.Advances on study of the origin and molecular mechanism of vasculogenic mimicry[J]. Chin J Neuro-oncol, 2011, 9(4): 272.
[11] YAO LL, ZHANG DF, ZHAO XL, et al. Dickkopf-1-promoted vasculogenic mimicry in non-small cell lung cancer is associated with EMT and development of a cancer stem-like cell phenotype[J]. Cell Mol Med, 2016, 20(9): 1673. doi: 10.1111/jcmm.12862
[12] PAULIS YW, SOETEKOUW PM, VERHEUL HM, et al. Signalling pathways in vasculogenic mimicry[J]. Biochim Biophys Acta, 2010, 1806(1): 18.
[13] LISSITZKY JC, PARRIAUX D, RISTORCELLI E, et al. CyclicAMP signaling as a mediator of vasculogenic mimicry in aggressive human melanoma cells in vitro[J]. Cancer Res, 2009, 69(3): 802. doi: 10.1158/0008-5472.CAN-08-2391
[14] KREBS LT, XUE Y, NORTON CR, et al. Notch signaling isessential for vascular morphogenesis in mice[J]. Genes Dev, 2000, 14: 1343.
[15] KHALKHALI-ELLIS Z, KIRSCHMANN DA, SEFTOR EA, et al. Divergence(s)in nodal signaling between aggressive melanoma and embryonic stem cells[J]. Int J Cancer, 2015, 136(5): 242. doi: 10.1002/ijc.29198
[16] ZHOU TJ, HUANG XH, GONG L, et al. Vasculogenic mimicry and hypoxia-inducible factor-1α expression in cervical squamous cell carcinoma[J]. Genet Mol Res, 2016, 15(1): 1.
[17] MOURAD-ZEIDAN AA, MELNIKOVA VO, WANG H, et al. Expression profiling of Galectin-3-depleted melanoma cells reveals its major role in melanoma cell plasticity and vasculogenic mimicry[J]. Am J Pathol, 2008, 173(6): 1839. doi: 10.2353/ajpath.2008.080380
[18] 屈波, 盛冠男, 余飞, 等. 逆转录病毒介导shRNA抑制Mig-7基因对人肝癌细胞血管生成拟态及体外侵袭转移的抑制作用[J]. 南方医科大学学报, 2016, 36(11): 1482. doi: 10.3969/j.issn.1673-4254.2016.11.06
[19] RONG X, HUANG B, QIU S, et al. Tumor-associated macrophages induce vasculogenic mimicry of glioblastomamultiforme through cyclooxygenase-2 activation[J]. Oncotarget, 2016, 7(51): 83976. doi: 10.18632/oncotarget.6930
[20] 段然, 梁筱, 李青峰. 恶性黑色素瘤的分子靶向治疗进展[J]. 实用肿瘤杂志, 2017, 32(6): 563.
[21] ORECCHIA P, CONTE R, BALZA E, et al. Targeting syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts[J]. Oncotarget, 2015, 6(35)37426. doi: 10.18632/oncotarget.6055
[22] SEFTOR EA, MELTZER PS, KIRSCHMANN DA, et al. Molecular determinants of human uveal melanoma invasion and metastasis[J]. Clin Exp Metastasis, 2002, 19(13): 233.
[23] WANG ZY, YOU DY, LU MN.Inhibitory effect of norcantharidin on melanoma tumor growth and vasculogenic mimicry by suppressing MMP-2 expression[J]. Oncol Lett, 2017, 13(5): 1660.
[24] LIANG XM, SUN R, ZHAO XL, et al. Rictor regulates the vasculogenic mimicry of melanoma via the AKT-MMP-2/9 pathway[J]. Cell Mol Med, 2017, 21(12)3579. doi: 10.1111/jcmm.13268
[25] WU K, HOUSE L, LIU, W, et al. Personalized Targeted Therapy for Lung Cancer[J]. Int J Mol Sci, 2012, 13: 11471. doi: 10.3390/ijms130911471
[26] WU SW, YU L, WANG DN, et al. Aberrant expression of CD133 in non-smallcell lung cancer and its relationship to vasculogenic mimicry[J]. BMC Cancer, 2012, 12: 535. doi: 10.1186/1471-2407-12-535
[27] WU SW, YU L, CHENG ZN, et al. Expression of maspin in non-small cell lung cancer and its relationship to vasculogenic mimicry[J]. Huazhong Univ Sci Technol(Med Sci), 2012, 32(3): 346. doi: 10.1007/s11596-012-0060-4
[28] LI YL, SUN BC, ZHAO XL, et al. Subpopulations of uPAR+ contribute to vasculogenic mimicry and metastasis in large cell lung cancer[J]. Exp Mol Pathol, 2015, 98: 136. doi: 10.1016/j.yexmp.2015.02.001
[29] WILLIAMSON SC, METCALF R, TRAPANI F, et al. Vasculogenic mimicry in small cell lung cancer[J]. Nat Commun, 2016, 7: 13322. doi: 10.1038/ncomms13322
[30] ABDEL-RAHMA O.Systemic therapy for hepatocellular carcinoma(HCC): from bench to bedside[J]. J Egypt Natl Canc Inst, 2013, 25(4): 165. doi: 10.1016/j.jnci.2013.08.002
[31] CHEN W, ZHENG R, BAADE PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115. doi: 10.3322/caac.21338
[32] CHEN J, ZHAO M, ZHANG ZS, et al. COE inhibits vasculogenic mimicry in hepatocellular carcinoma via suppressing Notch1 signaling[J]. J Ethnopharmacol, 2017, 208: 165. doi: 10.1016/j.jep.2017.07.007
[33] SU D, SUN BC, LIU TJ, et al. Slug promoted vasculogenic mimicry in hepatocellular carcinoma[J]. J Cell Mol Med, 2013, 17(8): 1038. doi: 10.1111/jcmm.12087
[34] CHEN J, WU ZF, ZHANG ZS, et al. Vasculogenic mimicry in hepatocellular carcinoma contributes to portal vein invasion[J]. Oncotarget, 2016, 7(47): 77987. doi: 10.18632/oncotarget.12867
[35] DENT R, TRUDEAU M, PRITCHARD KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence[J]. Clin Cancer Res, 2007, 13(6): 4429.
[36] CUI YF, LIU AH, AN DZ, et al. Claudin-4 is required for vasculogenic mimicry formation inhuman breast cancer cells[J]. Oncotarget, 2015, 6(13): 11087 doi: 10.18632/oncotarget.3571
[37] YAO N, REN K, JIANG CH, et al. Combretastatin A4 phosphate treatment induces vasculogenic mimicry formation of W256 breast carcinoma tumor in vitro and in vivo[J]. Tumor Biol, 2015, 36(11): 8499. doi: 10.1007/s13277-015-3508-x
[38] LI S, ZHANG Q, ZHOU L, et al. Inhibitory effects of compound DMBT on hypoxia-induced vasculogenic mimicry in human breast cancer[J]. Biomed Pharmacother, 2017, 96: 982. doi: 10.1016/j.biopha.2017.11.137
[39] PÀEZ-RIBES M, ALLEN E, HUDOCK J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis[J]. Cancer Cell, 2009, 15(3): 220. doi: 10.1016/j.ccr.2009.01.027